[EN] PSMA-TARGETING AMANITIN CONJUGATES<br/>[FR] CONJUGUÉS D'AMANITINE CIBLANT LE PSMA
申请人:HEIDELBERG PHARMA RES GMBH
公开号:WO2019057964A1
公开(公告)日:2019-03-28
The invention relates to a PSMA-targeting conjugate comprising (a) an amatoxin; (b) a small molecule PSMA-targeting moiety; and (c) optionally a linker linking said amatoxin and said small molecule PSMA-targeting moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate.
Stereoselectivity control in anomeric O-alkylation. Application to the synthesis of C2 symmetric glycoconjugates
作者:A. Lubineau、S. Escher、J. Alais、D. Bonnaffé
DOI:10.1016/s0040-4039(97)00830-7
日期:1997.6
Tetrabutylammonium salts strongly influence the stereoselectivity of O-anomeric alkylation and allows to shift from β to α selectivity. Allyl glucosaminide 7 prepared in this way, was used to synthesize the new type of C2 symmetric neoglycoconjugates 1a-c.
The host guest chemistry of cucurbiturils and the photochemistry of azastilbene derivatives are combined for the rationally adjusting multicolor emissions through forming different host guest complexes and their corresponding photochemical products. Cucurbit[8]uril (CB[8]) can bind with azastilbene derivatives to form supramolecular polymers emitting orange light. The supramolecular polymers further facilitate the [2 + 2] cycloaddition of C=C bonds in azastilbenes by UV irradiation, emitting blue light. Different from CB[8], cucurbit[7]uril (CB[7]) encapsulates azastilbene derivatives to form a dumbbell-shaped host-guest complex, emitting dark-purple light. This dumbbell-shaped host guest complex undergoes cis-isomerization after UV irradiation, thus emitting green light. Therefore, this strategy is promising for fabricating advanced stimuli-responsive fluorescent materials.
PSMA-TARGETING AMANITIN CONJUGATES
申请人:Heidelberg Pharma Research GmbH
公开号:US20200345807A1
公开(公告)日:2020-11-05
The invention relates to a PSMA-targeting conjugate comprising (a) an amatoxin; (b) a small molecule PSMA-targeting moiety; and (c) optionally a linker linking said amatoxin and said small molecule PSMA-targeting moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate.
[EN] SMALL-MOLECULE NADPH OXIDASE 2 INHIBITORS<br/>[FR] INHIBITEURS DE NADPH OXYDASE 2 À PETITE MOLÉCULE
申请人:UNIV COPENHAGEN
公开号:WO2021105497A1
公开(公告)日:2021-06-03
The invention provides compounds of Formula (II) which comprise two terminal 2-aminoquinoline moieties. They are novel and potent inhibitors of the p47phox-p22phox protein-protein interaction that can inhibit the assembly and thus activation of the multisubunit and superoxide-generating NADPH oxidase 2 complex. The compounds are therapeutically relevant as they can reduce cell damage in diseases where NADPH oxidase 2 is a major contributor to generation of reactive oxygen species (ROS) and oxidative stress.